New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, November 11, 2026

Back to the front page

From X

@StableBread

Fajasy on X

At the US$5.30/lb copper base case in American West Metals’ $AWMLF new pre-feasibility study (PFS) for its Storm copper project, the post-tax NPV (discounted at 7%) is US$119M, with a 32.8% IRR and a 3.6-year payback. The PEA (Storm’s first-pass study) showed US$149M at an 8% discount rate and a 46% IRR, on US$4.60/lb copper. So the PFS uses a higher copper price and a lower discount rate, and still values Storm lower. The PFS’s own sensitivity table shows ~US$110M at the PEA’s 8% rate, and post-tax FCF over the mine life fell to US$179M from US$191M, even though revenue rose to US$1.25B from US$839M. Extending the sensitivity table, each 10% drop in copper takes ~US$52M off the NPV. So at the PEA’s US$4.60/lb, 13.2% below the PFS’s price, Storm would be worth ~US$51M at 7% (US$118.9M − 1.32 × US$51.6M), about a third of the PEA’s US$149M. In other words, the higher copper price, not the mine plan, holds up the PFS’s NPV. The PFS also runs a spot case at US$6.53/lb copper (as of November 2), where the NPV rises to US$233M, with a 55.1% IRR and a 2.7-year payback. A 10% move in copper shifts the NPV by US$50-52M, and a 10% change in recovery by US$46-48M, against ~US$4M for a 10% change in capex. So the capex increase matters less to the value than to the funding. At ~US$52M per 10% move in copper, the NPV would reach zero near US$4.10/lb, ~36% below the November 9 price. At US$4.75/lb, the average London Metal Exchange (LME) price since January 2024 (per the PFS), the NPV would be ~US$65M. Copper is also near the top of its range, as the PFS’s US$6.53/lb spot price is just 3.1% below the US$6.74/lb LME high since January 2024. So I value Storm on the PFS’s US$5.30/lb base case rather than spot, since first copper is still at least three years away.
@ActAccordingly

PAA Research on X

As the headlines and memes arrive fast and furious on this feed regarding the latest revelations on Jensen, one name from yesteryear keeps coming to mind: Hank Greenberg. Is Jensen the Hank Greenberg of this cycle? The circumstances of their departures are quite different, but the implications could have meaningful parallels. $AIG had its tendrils in EVERYTHING at the peak of Hank's powers, just as $NVDA is in every nook and cranny of the AI trade today. Both companies ascended to an endemic status in their respective industries because of their leader's guile, will, aggressive use of capital, and other "financing arrangements". We know what happened with $AIG and the financial system in the post Hank-era, what's in store for $NVDA and all of the AI ecosystem players that rely on Jensen's backstops and other forms of circularity?

Investor Letters

All letters

Cat-Scratch Fervo

Fervo Energy raised $2 billion in its May IPO, then fell nearly 70% below issue price after a Morpheus short report, despite targeting 1 GW…

FRVO $2.3B
Doomberg 4 clicks
BKV · long

Bkv CORP

BKV Corp, public for less than two years, is an underfollowed natural-gas producer pursuing early-stage projects and a transition.

BKV $2B
Value Investors Club 1 click

Investment idea: Flowers Foods (FLO)

Flowers Foods cut its dividend to fund $300 million of debt reduction by 2027 after the $795 million Simple Mills acquisition lifted…

FLO $1.4B
Nugget Capital Partner's Substack

The Good, the Bad and the Ugly

Lam Research lifted its September revenue guide above consensus, while Microsoft’s capex cut reflects lease accounting and Meta’s AI…

LRCX $278B
Mispriced Assets

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 83 of 283

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

375 firms

Sectors

Ordered by how often our editor reaches for them.